CARISMA THERAP (CARM)
(Real Time Quote from BATS)
$1.39 USD
+0.02 (1.46%)
Updated May 17, 2024 12:26 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Carisma Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -86.88 | -19.88 | -0.34 | -22.40 | -107.50 |
Depreciation/Amortization & Depletion | 4.12 | 26.86 | 31.79 | 0.12 | 0.22 |
Net Change from Assets/Liabilities | -5.84 | 63.01 | -48.63 | 0.86 | -3.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.42 | -45.09 | -51.70 | -9.42 | 72.86 |
Net Cash From Operating Activities | -81.18 | 24.90 | -68.88 | -30.84 | -37.52 |
Property & Equipment | -1.13 | 0.03 | 0.00 | -0.01 | -0.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 73.54 | -54.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 72.41 | -53.97 | 0.00 | -0.01 | -0.14 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 31.42 | 0.00 | 176.13 | 38.11 | 35.36 |
Issuance (Repayment) of Debt | -1.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 32.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 62.18 | 0.00 | 176.13 | 38.11 | 35.36 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 53.41 | -29.07 | 107.25 | 7.27 | -2.30 |
Cash at Beginning of Period | 24.19 | 162.66 | 55.41 | 48.14 | 50.44 |
Cash at End of Period | 77.61 | 133.58 | 162.66 | 55.41 | 48.14 |
Diluted Net EPS | -2.59 | -2.00 | -0.04 | -3.80 | -23.60 |
Fiscal Year End for Carisma Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -18.98 | -86.88 | -65.92 | -44.52 | -24.64 |
Depreciation/Amortization & Depletion | 1.69 | 4.12 | 3.40 | 2.70 | 1.99 |
Net Change from Assets/Liabilities | -7.86 | -5.84 | -7.53 | -5.13 | -4.44 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.72 | 7.42 | 4.97 | 2.86 | 1.56 |
Net Cash From Operating Activities | -22.43 | -81.18 | -65.08 | -44.08 | -25.53 |
Property & Equipment | -0.02 | -1.13 | -0.57 | -0.38 | -0.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 73.54 | 62.54 | 32.54 | -3.46 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.02 | 72.41 | 61.97 | 32.16 | -3.60 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.29 | 31.42 | 30.73 | 30.69 | 30.64 |
Issuance (Repayment) of Debt | -1.32 | -1.30 | -1.78 | -0.21 | -0.11 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.38 | 32.06 | 33.13 | 33.63 | 37.21 |
Net Cash from Financing Activities | 1.35 | 62.18 | 62.08 | 64.11 | 67.74 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -21.09 | 53.41 | 58.97 | 52.19 | 38.61 |
Cash at Beginning of Period | 77.61 | 24.19 | 24.19 | 24.19 | 24.19 |
Cash at End of Period | 56.52 | 77.61 | 83.16 | 76.38 | 62.81 |
Diluted Net EPS | -0.46 | 0.36 | -0.53 | -0.49 | -1.93 |